Skip to content

Treatment of Localized Low Grade Lymphomas

Phase III Study of Treatment of Localized Lymphomas: Radiotherapy Versus Radio-Chemotherapie

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00536458
Enrollment
132
Registered
2007-09-27
Start date
1999-03-31
Completion date
2006-12-31
Last updated
2007-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Low-Grade

Keywords

localized low grade lymphoma, Chemotherapy, Radiotherapy, Molecular analyses, primary

Brief summary

To compare localiezd radiotherapy to localized radiotherapy followed by 6 cycles of chemotherapy in the treatment of localiezd low grade lymphoma

Detailed description

The standard treatment ol localized low grade lymphomas is Radiotherapy alone can offer long term remissions to some patients . No study have clearly demonstrated the interest of chemotherapy. The purpose of the study is to determine wether prednisone administrated after first line local radiotherapy (30 GY) can pre in the treatment of localized low grade lymphomas of adult patients

Interventions

PROCEDUREradiotherapy

mini chep+ radiotherapy

DRUGMINI CHEP

chemotherapy minichep 6 courses

Sponsors

French Innovative Leukemia Organisation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Low grade lymphoma defined according to the Ann Arbor classification * localized

Exclusion criteria

* Subjects unable to signed informed consent * Pregnancy

Design outcomes

Primary

MeasureTime frame
failure free survival at 5 years5 years

Secondary

MeasureTime frame
overall survival at 5 years5 years
response rates at the end of the treatment6 months
prognstic value of molecular analyses in blood and marrow6 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026